A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

NCT04085172 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

396

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Guanfacine hydrochloride (TAK-503)
DRUG: Atomoxetine hydrochloride
OTHER: Placebo

Sponsor

Shire

Collaborators

[object Object]